Trials / Unknown
UnknownNCT02136836
Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 860 (estimated)
- Sponsor
- Yonsei University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to investigate the proportion of HER2 overexpression in gastric cancer patients group, to evaluate the relation of HER2 overexpression with prognosis, and to analyze the proportion of herceptin applied to patients in clinical field. Furthermore, the investigators are going to reevaluate the clinical benefit of Herceptin for survival prolongation compared to chemotherapy only.
Conditions
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2015-03-01
- First posted
- 2014-05-13
- Last updated
- 2014-05-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02136836. Inclusion in this directory is not an endorsement.